The First Experiences With Reassessments and Appraisals of Conditionally Approved Expensive and Orphan Drugs in the Netherlands (2006-2013)
Value in Health - United Kingdom
doi 10.1016/j.jval.2013.08.308
Full Text
Open PDFAbstract
Available in full text
Date
November 1, 2013
Authors
Publisher
Elsevier BV